Cargando…

Blinatumomab-induced T cell activation at single cell transcriptome resolution

BACKGROUND: Bi-specific T-cell engager (BiTE) antibody is a class of bispecific antibodies designed for cancer immunotherapy. Blinatumomab is the first approved BiTE to treat acute B cell lymphoblastic leukemia (B-ALL). It brings killer T and target B cells into close proximity, activating patient’s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huo, Yi, Sheng, Zhen, Lu, Daniel R., Ellwanger, Daniel C., Li, Chi-Ming, Homann, Oliver, Wang, Songli, Yin, Hong, Ren, Ruibao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923532/ https://www.ncbi.nlm.nih.gov/pubmed/33648458 http://dx.doi.org/10.1186/s12864-021-07435-2

Ejemplares similares

Systematic comparison of high-throughput single-cell RNA-seq methods for immune cell profiling
por: Yamawaki, Tracy M., et al.
Publicado: (2021)

Blinatumomab-associated vasculitis
por: Liau, MeiQi May, et al.
Publicado: (2017)

Relapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
por: Jacoby, Elad
Publicado: (2019)

Immunotherapeutic potential of blinatumomab-secreting γ9δ2 T Cells
por: Wu, Shang-Ju, et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia
por: Le Jeune, Caroline, et al.
Publicado: (2016)

Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
por: Lee, Kum Ja, et al.
Publicado: (2016)

Treatment of Relapsed B/T-cell Mixed Phenotype Acute Leukemia With Blinatumomab
por: Abdo, Yasmeen, et al.
Publicado: (2023)

Blinatumomab as bridging therapy in paediatric B‐cell acute lymphoblastic leukaemia complicated by invasive fungal disease
por: Yeoh, Daniel K., et al.
Publicado: (2022)

Spatiotemporal dynamics of inner ear sensory and non-sensory cells revealed by single-cell transcriptomics
por: Jan, Taha A., et al.
Publicado: (2021)

Spatial transcriptomics deconvolution at single-cell resolution using Redeconve
por: Zhou, Zixiang, et al.
Publicado: (2023)

Advancements in Therapy for Acute Lymphoblastic Leukemia: Blinatumomab
por: Hladnik,1, Lindsay, et al.
Publicado: (2016)

Blinatumomab in Ph+ B-ALL: present and perspectives
por: Papayannidis, Cristina, et al.
Publicado: (2017)

Recent advances on blinatumomab for acute lymphoblastic leukemia
por: Zhao, Juanjuan, et al.
Publicado: (2019)

Cytokine Release Syndrome Following Blinatumomab Therapy
por: Ojemolon, Pius E, et al.
Publicado: (2022)

SPASCER: spatial transcriptomics annotation at single-cell resolution
por: Fan, Zhiwei, et al.
Publicado: (2022)

Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
por: Portell, Craig A, et al.
Publicado: (2013)

Blinatumomab induces complete response in refractory PTLD after hematopoietic cell transplantation
por: Janardan, Sanyukta, et al.
Publicado: (2022)

Positioning blinatumomab in the frontline of adult B-cell acute lymphoblastic leukemia treatment
por: Pourhassan, Hoda, et al.
Publicado: (2023)

Bispecific T-cell engaging antibodies in B-cell precursor acute lymphoblastic leukemias: focus on blinatumomab
por: Ribera, Jose-Maria, et al.
Publicado: (2020)

Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
por: Wei, Andrew H., et al.
Publicado: (2021)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

Lineage Conversion in Pediatric B-Cell Precursor Acute Leukemia under Blinatumomab Therapy
por: Semchenkova, Alexandra, et al.
Publicado: (2022)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL
por: Duell, J, et al.
Publicado: (2017)

Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration
por: Cao, Han-Yu, et al.
Publicado: (2023)

Infectious Risks and Complications in Adult Leukemic Patients Receiving Blinatumomab
por: So, Wonhee, et al.
Publicado: (2018)

Pharmacokinetic and Pharmacodynamic Relationship of Blinatumomab in Patients with Non-Hodgkin Lymphoma
por: Hijazi, Youssef, et al.
Publicado: (2018)

Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies
por: Clements, John David, et al.
Publicado: (2019)

The changing mouse embryo transcriptome at whole tissue and single-cell resolution
por: He, Peng, et al.
Publicado: (2020)

Frontline Blinatumomab in Older Adults with Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
por: Niyongere, Sandrine, et al.
Publicado: (2020)

Outcomes of relapsed B-cell acute lymphoblastic leukemia after sequential treatment with blinatumomab and inotuzumab
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

The Epigenetic Regulation of Blinatumomab Gene Expression: Tumor Cell-dependent T cell Response against Lymphoma Cells and Cytotoxic Activity
por: Naddafi, Fatemeh, et al.
Publicado: (2019)

Deciphering transcriptome alterations in bone marrow hematopoiesis at single-cell resolution in immune thrombocytopenia
por: Liu, Yan, et al.
Publicado: (2022)

Decoding the transcriptome of calcified atherosclerotic plaque at single-cell resolution
por: Alsaigh, Tom, et al.
Publicado: (2022)

The transcriptomic landscape of normal and ineffective erythropoiesis at single-cell resolution
por: Doty, Raymond T., et al.
Publicado: (2023)

Cell type identification from single-cell transcriptomes in melanoma
por: Huo, Qiuyan, et al.
Publicado: (2021)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Stein, Anthony, et al.
Publicado: (2018)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_75c4rnp85i07cbd6kr25vhuill